Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - formoterol fumarate, quantity: 12 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - for long-term, regular treatment of reversible airways obstruction in asthma (including nocturnal asthma and exercised-induced asthma) in patients aged 5 years or more who are receiving inhaled or oral corticosteroids. it should not be used in patients whose asthma can be managed by occasional use of short-acting inhaled beta-2 agonists. indications as at 27 march 2001: for the long-term regular treatment of reversible airways obstruction in asthma (including nocturnal asthma and exercise-induced asthma) in patients aged 5 years or more who are receiving inhaled or oral corticosteroids. it should not be used in patients whose asthma can be managed by occasional use of short-acting inhaled beta-2 agonists. for the prophylaxis and treatment of bronchoconstriction in patients with reversible or irreversible chronic obstructive pulmonary disease (copd).

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - budesonide, quantity: 160 microgram; formoterol fumarate dihydrate, quantity: 4.5 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate - asthma rilast turbuhaler is indicated in adults and adolescents (12 years and older), for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see section 4.2 dose and method of administration). chronic obstructive pulmonary disease (copd) rilast turbuhaler is indicated for the symptomatic treatment of moderate to severe copd (fev1 < or = 50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or a history of recurrent exacerbations. rilast turbuhaler is not indicated for the initiation of bronchodilator therapy in copd.

Ireland - English - HPRA (Health Products Regulatory Authority)

meda health sales ireland limited - formoterol fumatrate dihydrate - powder for inhalation - 12 microgram - selective beta-2-adrenoreceptor agonists

Israel - English - Ministry of Health

novartis israel ltd - formoterol fumarate dihydrate - powder for inhalation - formoterol fumarate dihydrate 12 mcg - formoterol - formoterol - foradil is indicated in asthma ( including nocturnal asthma and exercise-induced symptoms) in those treated with inhaled corticosteroids who also require a long-acting beta agonist in accordance with current treatment guidelines.prophylaxis and treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (copd) including chronic bronchitis and emphysema.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - formoterol fumarate - powder for inhalation - formoterol fumarate 9 mcg/dose - formoterol - formoterol - for the relief of broncho-obstructive symptoms and prevention of exercise-induced symptoms in asthmatics when adequate treatment with corticosteroids is not sufficient. for the relief of bronco-obstructive symptoms in patients with chronic obstructive pulmonary disease (copd).

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - formoterol fumarate - powder for inhalation - formoterol fumarate 9 mcg/dose - formoterol - formoterol - for the relief of broncho-obstructive symptoms and prevention of exercise-induced symptoms in asthmatics when adequate treatment with corticosteroids is not sufficient for the relief of bronco-obstructive symptoms in patients with chronic obstructive pulmonary disease (copd).

Ireland - English - HPRA (Health Products Regulatory Authority)

meda health sales ireland limited - formoterol fumatrate dihydrate - powder for inhalation - 6 microgram - selective beta-2-adrenoreceptor agonists

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

orient europharma (m) sdn bhd - beclomethasone dipropionate; formoterol fumarate dihydrate; glycopyrronium bromide -

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - 38473 - information system, patient record - information system for patient records

Israel - English - Ministry of Health

kamada ltd, israel - beclometasone dipropionate anhydrous; formoterol fumarate dihydrate - pressurised solution - formoterol fumarate dihydrate 6 mcg/dose; beclometasone dipropionate anhydrous 100 mcg/dose - formoterol and beclometasone - beclometasone - foster is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist or- patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists.copd :symptomatic treatment of patients with severe copd (fev1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.